U Novak
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland
Moccia A, Mingrone W, Novak U, Pfleger C, Richter P, Rütti M, Schmidt A, Stenner F, Voegeli M, Zander T, Zucca E, Mey U, Lang N, Aeppli S, Güsewell S, Bargetzi M, Caspar C, Brülisauer D, Ebnöther M, Fehr M, Fischer N, Ghilardi G, Krasniqi F, Hitz F. Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland. Hematol Oncol 2020; 39:196-204.
Dec 23, 2020Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland
Dec 23, 2020Hematol Oncol 2020; 39:196-204
Moccia A A, Mingrone W, Novak U, Pfleger C, Richter P, Rütti M, Schmidt A, Stenner F, Voegeli M, Zander T, Zucca E, Mey U, Lang N, Aeppli Stefanie, Güsewell Sabine, Bargetzi M, Caspar C, Brülisauer D, Ebnöther M, Fehr Martin, Fischer N, Ghilardi G, Krasniqi F, Hitz Felicitas
Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
Hitz F, Driessen C, Mey U, Samaras P, Vilei S, Stüdeli S, Rondeau S, Seipel K, Novak U, Silzle T, Besse L, Hess D, Pabst T, Kraus M, Swiss Group for Clinical Cancer Research SAKK. Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood Cancer J 2019; 9:70.
Aug 27, 2019Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
Aug 27, 2019Blood Cancer J 2019; 9:70
Hitz Felicitas, Driessen Christoph, Mey U, Samaras P, Vilei S Berardi, Stüdeli S, Rondeau S, Seipel K, Novak U, Silzle Tobias, Besse Lenka, Hess Dagmar, Pabst T, Kraus Marianne, Swiss Group for Clinical Cancer Research SAKK